Search

Your search keyword '"Vose, Julie M."' showing total 888 results

Search Constraints

Start Over You searched for: Author "Vose, Julie M." Remove constraint Author: "Vose, Julie M." Language english Remove constraint Language: english
888 results on '"Vose, Julie M."'

Search Results

1. Long-term outcomes of patients with large B-cell lymphoma treated with axicabtagene ciloleucel and prophylactic corticosteroids

2. High-grade B-cell lymphoma, not otherwise specified: CNS involvement and outcomes in a multi-institutional series

3. Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study

5. Integrative analysis of clinicopathological features defines novel prognostic models for mantle cell lymphoma in the immunochemotherapy era: a report from The North American Mantle Cell Lymphoma Consortium

6. Bridging therapy with axicabtagene ciloleucel for large B-cell lymphoma: results from the US Lymphoma CAR-T Consortium

7. Outcomes of patients with blastoid and pleomorphic variant mantle cell lymphoma

8. High-grade B-cell lymphoma, not otherwise specified: a multi-institutional retrospective study

9. 2024 Statistics May Impact Next Decade of Cancer Treatment

10. Severity of Cytokine Release Syndrome Influences Outcome After Axicabtagene Ciloleucel for Large B cell Lymphoma: Results from the US Lymphoma CAR-T Consortium

11. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee

14. ALK-negative anaplastic large cell lymphoma: features and outcomes of 235 patients from the International T-Cell Project

15. Complementary and Alternative Medicine in Cancer Care: Does It Have a Role?

16. Electronic Medical Records and Physicians: A Love-Hate Relationship

17. Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogenetics

19. 2023 Year in Review: Topics in Hematology/Oncology

20. Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial

23. Multidisciplinary Team Approach Is Integral to Oncology Care

29. An International Real-World Analysis of Relapsed/Refractory Lymphoma Occurring During Pregnancy

30. Hope After Salvage Therapy Fails: Novel Agents for Relapsed/Refractory Hodgkin Lymphoma

31. Care Plans, Education Improve Long-term Quality of Life

35. LEAD 2022: Enriching Experiences for Women in Hematology & Oncology

36. Burnout: Which Way Out?

39. Role of Cytotoxic Therapy with Hematopoietic Cell Transplantation in the Treatment of Hodgkin Lymphoma: Guidelines from the American Society for Blood and Marrow Transplantation

41. Global microRNA expression profiling uncovers molecular markers for classification and prognosis in aggressive B-cell lymphoma

42. Early Failure of Frontline Rituximab-Containing Chemo-immunotherapy in Diffuse Large B Cell Lymphoma Does Not Predict Futility of Autologous Hematopoietic Cell Transplantation

44. Outcomes of Hematopoietic Cell Transplantation for Diffuse Large B Cell Lymphoma Transformed from Follicular Lymphoma

47. American Society of Hematology: 64th Annual Meeting Review

48. ABCL-191 Extended Follow-Up Beyond 2.5 Years Demonstrates Long-Term Efficacy in Complete Responders Following Epcoritamab Monotherapy in Relapsed or Refractory Large B-Cell Lymphoma (R/R LBCL)

49. Extended Follow-Up Beyond 2 .5 Years Demonstrates Long-Term Efficacy in Complete Responders Following Epcoritamab Monotherapy in Relapsed or Refractory Large B-Cell Lymphoma (R/R LBCL)

50. Final results of a phase II study of CHOEP plus lenalidomide as initial therapy for patients with stage II–IV peripheral T‐cell lymphoma.

Catalog

Books, media, physical & digital resources